Experienced in Acute Myelomonocytic Leukemia

Dr. Alison D. Savage

Asante Three Rivers Medical Center LLC
Grants Pass, OR
Experienced
in Acute Myelomonocytic Leukemia
Specialties:Hematology Oncology | Hematology | Oncology
Accepting New Patients
Offers Telehealth
OverviewInsuranceLocationsClinical Research

Overview

Alison Savage is a Hematologist Oncology specialist and a Hematologist in Grants Pass, Oregon. Dr. Savage and is rated as an Experienced provider by MediFind in the treatment of Acute Myelomonocytic Leukemia. Her top areas of expertise are Paget Disease of the Breast, Chronic Lymphocytic Leukemia (CLL), Lung Cancer, Virilizing Ovarian Tumor, and Bone Marrow Aspiration. Dr. Savage is currently accepting new patients.

Her clinical research consists of participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in OR
Hospital Affiliations
Fairchild Medical Center
Asante Ashland Community Hospital
Providence Medford Medical Center
Asante Three Rivers Medical Center
Asante Rogue Regional Medical Center
Languages Spoken
English
Gender
Female

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  BridgeSpan
  •  PacificSource
  •  Moda Health
  •  Regence
  •  Prominence Health

Locations

ASANTE THREE RIVERS MEDICAL CENTER LLC
500 Sw Ramsey Ave, Grants Pass, OR 97527
541-472-7000
Other Locations
ASANTE
2825 E Barnett Rd, Medford, OR 97504
541-789-7000

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: February 25, 2025
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
Randomized Study of Erlotinib vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: February 25, 2025
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: February 25, 2025
Intervention Type: Other, Procedure, Biological
Study Drug: Nivolumab
Study Phase: Phase 3
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Enrollment Status: Active_not_recruiting
Publish Date: February 25, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Nivolumab
Study Phase: Phase 3
Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer (COBRA)
Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer (COBRA)
Enrollment Status: Active_not_recruiting
Publish Date: February 04, 2025
Intervention Type: Drug, Other
Study Drugs: Capecitabine, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 2/Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
S1602, A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming With Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-muscle Invasive Bladder Cancer
S1602, A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming With Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-muscle Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 29, 2024
Intervention Type: Biological, Other
Study Drugs: Bacillus of Calmette-Guerin, Bacillus of Calmette-Guerin Tokyo-172 Strain Solution, Bacillus of Calmette-Guerin Tokyo-172 Strain Vaccine
Study Phase: Phase 3
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 03, 2024
Intervention Type: Drug, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Paclitaxel
Study Phase: Phase 3
View 7 Less Clinical Trials
Similar Doctors
Expertise in
10
conditions
Dr. Edward J. Ottenheimer
Hematology Oncology | Hematology | Oncology
Expertise in
10
conditions
Dr. Edward J. Ottenheimer
Hematology Oncology | Hematology | Oncology
1813 W Harvard Ave, Suite 436, 
Roseburg, OR 
 (54.8 mi)
541-673-0496
Experience:
43+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Edward Ottenheimer is a Hematologist Oncology specialist and a Hematologist in Roseburg, Oregon. Dr. Ottenheimer has been practicing medicine for over 43 years and is rated as an Advanced provider by MediFind in the treatment of Acute Myelomonocytic Leukemia. His top areas of expertise are Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, Splenomegaly, and Vitamin B12 Deficiency. Dr. Ottenheimer is currently accepting new patients.

Expertise in
58
conditions
Dr. Brett A. Poisson
Hematology Oncology | Hematology | Oncology
Expertise in
58
conditions
Dr. Brett A. Poisson
Hematology Oncology | Hematology | Oncology

Asante Three Rivers Medical Center LLC

500 Sw Ramsey Ave, 
Grants Pass, OR 
541-472-7000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Brett Poisson is a Hematologist Oncology specialist and a Hematologist in Grants Pass, Oregon. Dr. Poisson and is rated as a Distinguished provider by MediFind in the treatment of Acute Myelomonocytic Leukemia. His top areas of expertise are Waldenstrom Macroglobulinemia, Gaucher Disease Type 2, Gaucher Disease, and Gaucher Disease Type 3. Dr. Poisson is currently accepting new patients.

Expertise in
57
conditions
Dr. Mujahid A. Rizvi
Hematology Oncology | Hematology | Oncology
Expertise in
57
conditions
Dr. Mujahid A. Rizvi
Hematology Oncology | Hematology | Oncology

Asante Three Rivers Medical Center LLC

500 Sw Ramsey Ave, 
Grants Pass, OR 
541-472-7000
Languages Spoken:
English, Hindi, Urdu
See accepted insurances
Accepting New Patients
Offers Telehealth

Mujahid Rizvi is a Hematologist Oncology specialist and a Hematologist in Grants Pass, Oregon. Dr. Rizvi and is rated as a Distinguished provider by MediFind in the treatment of Acute Myelomonocytic Leukemia. His top areas of expertise are Appendix Cancer, Hairy Cell Leukemia (HCL), Reticuloendotheliosis, Colorectal Cancer, and Bone Marrow Aspiration. Dr. Rizvi is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile